Antivascular therapy for orthotopic human ovarian carcinoma through blockade of the vascular endothelial growth factor and epidermal growth factor receptors. [electronic resource]
Producer: 20051207Description: 4923-33 p. digitalISSN:- 1078-0432
- Animals
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Blood Vessels -- drug effects
- Blotting, Western
- Cell Line
- Cell Line, Tumor
- Cell Proliferation -- drug effects
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Drug Resistance, Neoplasm
- ErbB Receptors -- antagonists & inhibitors
- Female
- Humans
- Immunohistochemistry
- Mice
- Mice, Inbred C57BL
- Mice, Inbred CBA
- Mice, Nude
- Ovarian Neoplasms -- blood supply
- Paclitaxel -- administration & dosage
- Platelet Endothelial Cell Adhesion Molecule-1 -- analysis
- Proliferating Cell Nuclear Antigen -- analysis
- Purines -- administration & dosage
- Survival Analysis
- Treatment Outcome
- Vascular Endothelial Growth Factor A -- antagonists & inhibitors
- Xenograft Model Antitumor Assays -- methods
No physical items for this record
Publication Type: Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
There are no comments on this title.
Log in to your account to post a comment.